Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
LUCD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)913.12K
Market Cap
$107.92M
Enterprise Value$166.96M
Total Cash (Recent Filing)$25.24M
Total Debt (Recent Filing)$35.27M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Nov 17, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding108,194,610
10 Day Avg. Volume710,688
30 Day Avg. Volume913,116
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue40.01
Enterprise Value/Gross Profit-59.18
Enterprise Value/Ebitda-2.74
Forecast
1Y Price Target
$3.39Price Target Upside239.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market PenetrationLucid's efforts to deepen its market penetration through a comprehensive strategy should drive revenue higher over time.
Medicare CoverageMedicare coverage of LUCD's flagship EsoGuard test could be nearing, which might not yet be reflected in the stock price.
PartnershipsLUCD partnered with a major health system to expand access to its EsoGuard testing program, which is expected to broaden adoption and drive topline growth.
Bears Say
Financial LossLUCD reported revenue below consensus with a wider GAAP loss per share than expected.
Regulatory DelaysThe CAC meeting delays the MolDX decision, pushing it to late 2025 or early 2026.
Revenue PerformanceLucid reported 1Q25 revenue that was below our estimate and FactSet consensus.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.73 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Lucid Diagnostics’s market cap is $107.92M.
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Nov 17, 2025 which is in 95 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Aug 13, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.014.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -0.11.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 108,194,610 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went up 7.563%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.39 (239.00% Upside)
$3.39 (239.00% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $456.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.69%
12-Months-Change
Fundamentals
Return on Equity
-1897.35%
Trailing 12-Months
Asset Growth
2.33%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics (LUCD) is a medical diagnostics company focused on the development and commercialization of diagnostic tests for the early detection of esophageal precancer and cancer. The company's core product is the EsoGuard Esophageal DNA Test, which is designed to detect genetic abnormalities indicative of esophageal cancer and precancerous conditions, such as Barrett's Esophagus, using a non-invasive method. Lucid Diagnostics operates in the healthcare sector, specifically within the molecular diagnostics and gastrointestinal health fields.
LUCD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant advancements in test volume, insurance coverage, and clinical validation. The company's financial position is strong, bolstered by recent financing. However, challenges remain in revenue recognition and the reimbursement environment, which are expected to improve with strategic efforts underway.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$3.39
▲(239.00% Upside)
Technical Analysis
Ownership Overview
2.76% Insiders
1.06% Mutual Funds
0.01% Other Institutional Investors
91.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---